BlackRock Advisors’s Ocular Therapeutix OCUL Stock Holding History

BlackRock Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$54K	Sell	6,508 -536	-8%	-$4.16K	﹤0.01%	3237
2016 Q3	$48K	Buy	7,044 +1,925	+38%	+$11.7K	﹤0.01%	3264
2016 Q2	$25K	Hold	5,119	–	–	﹤0.01%	3394
2016 Q1	$49K	Buy	5,119 +1,252	+32%	+$9.48K	﹤0.01%	3164
2015 Q4	$36K	Sell	3,867 -3,369	-47%	-$36.4K	﹤0.01%	3314
2015 Q3	$102K	Buy	7,236 +645	+10%	+$13K	﹤0.01%	3094
2015 Q2	$139K	Buy	6,591 +3,882	+143%	+$96.2K	﹤0.01%	3020
2015 Q1	$114K	Buy	2,709 +568	+27%	+$18.7K	﹤0.01%	2976
2014 Q4	$50K	Sell	2,141 -970	-31%	-$16.3K	﹤0.01%	3274
2014 Q3	$47K	Buy	+3,111	New	+$46K	﹤0.01%	3280

Other funds holding OCUL

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

BlackRock Advisors's OCUL Position: Q4 2016 in Review

BlackRock Advisors reduced its Ocular Therapeutix (OCUL) stake by 7.6% in Q4 2016, selling an estimated $4.16K and leaving 6,508 shares worth $54K. The position accounts for ﹤0.01% of the portfolio, ranked #3237.

BlackRock Advisors first reported a position in OCUL in Q3 2014 and has held it in 10 quarters since. The position peaked at $139K in Q2 2015. 76 funds tracked by Wall St. Rank hold OCUL as of Q4 2016.

BlackRock Advisors held 6,508 shares of Ocular Therapeutix worth $54K as of Q4 2016.
BlackRock Advisors sold 536 Ocular Therapeutix shares in Q4 2016, an estimated $4.16K.
Ocular Therapeutix made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3237 holding.
BlackRock Advisors first reported a position in Ocular Therapeutix in Q3 2014 and has held it in 10 quarters since.
BlackRock Advisors's Ocular Therapeutix position peaked at $139K in Q2 2015.
76 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.